Clinical trials are moving toward faster data, faster signals, and faster decisions.
The FDA recently announced real-time clinical trial proof-of-concepts and a proposed pilot program designed to help trial endpoints and data signals move to the agency in real time. The agency also opened a Request for Information, with comments due by May 29, 2026.
That’s a major shift for clinical development.
But it also raises an important question: Can patient recruitment keep up?
Faster trial data will not solve slow patient identification.
It won’t fix shallow prescreening.
It won’t reduce referral waste if patients are still being passed downstream before they are well-matched, informed, and ready.
For sponsors and CROs, the next bottleneck may not only be data speed. It’s recruitment readiness.
That means asking:
- Are we reaching the right patients early enough?
- Are patients being prescreened before referral?
- Do they understand what participation involves?
- Can we see where patients are progressing or dropping off?
- Are sites receiving better-fit referrals?
Antidote’s precision recruitment model is built around this need.
By combining digital recruitment expertise, trusted partner-based outreach, patient-centric communication, careful prescreening, and site follow-up support, Antidote helps move beyond simple referral volume.
Because in a faster trial environment, more names in the funnel will not be enough.
Better-matched, better-informed, better-qualified patients will matter more.
